Journal: Journal of Community Hospital Internal Medicine Perspectives

Article Title: The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice

doi: 10.1080/20009666.2021.1978652

Figure Lengend Snippet: Baseline characteristics of participant patients on TKIs

Article Snippet: The prevalence of QTc prolongation in patients on TKIs with or without diabetes The * indicated a significant difference (p < 0.05, Chi-square test)The ** indicated a very significant difference (p < 0.01, Chi-square test) In comparison, the percentage of prolonged QTc interval in diabetic patients was increased from 21.7% (before treatment of TKIs) to 40% (after treatment of TKIs) and difference is significantly different (n = 60, p = 0.03, Chi-square test) ( ).

Techniques:

Journal: Journal of Community Hospital Internal Medicine Perspectives

Article Title: The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice

doi: 10.1080/20009666.2021.1978652

Figure Lengend Snippet: The prevalence of QTc prolongation in patients on TKIs with or without diabetes

Article Snippet: The prevalence of QTc prolongation in patients on TKIs with or without diabetes The * indicated a significant difference (p < 0.05, Chi-square test)The ** indicated a very significant difference (p < 0.01, Chi-square test) In comparison, the percentage of prolonged QTc interval in diabetic patients was increased from 21.7% (before treatment of TKIs) to 40% (after treatment of TKIs) and difference is significantly different (n = 60, p = 0.03, Chi-square test) ( ).

Techniques:

Journal: Journal of Community Hospital Internal Medicine Perspectives

Article Title: The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice

doi: 10.1080/20009666.2021.1978652

Figure Lengend Snippet: The prevalence of QTc prolongation in patients on TKIs with or without risk factors modifications

Article Snippet: The prevalence of QTc prolongation in patients on TKIs with or without diabetes The * indicated a significant difference (p < 0.05, Chi-square test)The ** indicated a very significant difference (p < 0.01, Chi-square test) In comparison, the percentage of prolonged QTc interval in diabetic patients was increased from 21.7% (before treatment of TKIs) to 40% (after treatment of TKIs) and difference is significantly different (n = 60, p = 0.03, Chi-square test) ( ).

Techniques:

Journal: Journal of Community Hospital Internal Medicine Perspectives

Article Title: The Risk of QTc Prolongation in Non-Diabetic and Diabetic Patients Taking Tyrosine Kinase Inhibitors (TKIs)- A Patient Safety Project at a Private Oncology Practice

doi: 10.1080/20009666.2021.1978652

Figure Lengend Snippet: The QTc interval distributions of TKIs

Article Snippet: The prevalence of QTc prolongation in patients on TKIs with or without diabetes The * indicated a significant difference (p < 0.05, Chi-square test)The ** indicated a very significant difference (p < 0.01, Chi-square test) In comparison, the percentage of prolonged QTc interval in diabetic patients was increased from 21.7% (before treatment of TKIs) to 40% (after treatment of TKIs) and difference is significantly different (n = 60, p = 0.03, Chi-square test) ( ).

Techniques:

Journal: BMC Medicine

Article Title: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

doi: 10.1186/1741-7015-10-28

Figure Lengend Snippet: Effect of TKI treatment on cell growth inhibition and apoptosis induction . Effect of TKIs gefitinib, erlotinib, and afatinib and cetuximab on the growth (A) and caspase3/7 activity (B) of HCC827, H292, H358, H1650, and H1975 cells after 72-h incubation. Independent experiments were repeated six times and one representative result is shown. Points, mean value of six identical wells of a single representative experiments; bars, SD (n = 6).

Article Snippet: TKIs gefitinib (AstraZeneca, Cheshire, UK), erlotinib (AstraZeneca, Cheshire, UK), and the EGFR+HER2 specific afatinib (Boehringer Ingelheim, Ingelheim, Germany) stocks of 10 mM were prepared in dimethyl sulfoxide (DMSO) and stored at -80°C.

Techniques: Inhibition, Activity Assay, Incubation

Journal: BMC Medicine

Article Title: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

doi: 10.1186/1741-7015-10-28

Figure Lengend Snippet: Effect of adding an EGFR siRNA to gefitinib on cell growth inhibition . Lung cancer cells were treated with gefitinib 24 h before the EGFR siRNA transfection. After transfecting the siRNA, the cells were incubated for another 48 h, after which cellular growth was assessed by the MTS assay. (A) shows the combination effect of gefitinib and siRNA. * P < 0.05 and ** P < 0.01 compared to controls with only siRNA transfection. "black triangle" P < 0.05 and "double black triangles" P < 0.01 compared to agents plus control siRNA. Median-effect plot (B) , dose-effect curve (C) , Fa-CI plot (D) , and normalized isobologram (E) were computationally generated by Biosoft CalcuSyn program with EGFR siRNA and combined to gefitinib in H358 cells. Similar additive effect was found in all the combinations in all the five cell lines (data not shown).

Article Snippet: TKIs gefitinib (AstraZeneca, Cheshire, UK), erlotinib (AstraZeneca, Cheshire, UK), and the EGFR+HER2 specific afatinib (Boehringer Ingelheim, Ingelheim, Germany) stocks of 10 mM were prepared in dimethyl sulfoxide (DMSO) and stored at -80°C.

Techniques: Inhibition, Transfection, Incubation, MTS Assay, Control, Generated

Journal: BMC Medicine

Article Title: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab

doi: 10.1186/1741-7015-10-28

Figure Lengend Snippet: Enhancement of apoptosis induction by the combination of EGFR siRNA plus gefitinib or erlotinib . Lung cancer cells were treated with different drugs 24 h before the EGFR siRNA transfection. Forty-eight hours post transfection, the cell cultures were assayed for caspase-3/7 activity. ( A : gefitinib; B : erlotinib). * P < 0.05 and ** P < 0.01 compared to controls with siRNA transfection alone. "black triangle" P < 0.05 and "double black triangles" P < 0.01 compared to agents plus control siRNA.

Article Snippet: TKIs gefitinib (AstraZeneca, Cheshire, UK), erlotinib (AstraZeneca, Cheshire, UK), and the EGFR+HER2 specific afatinib (Boehringer Ingelheim, Ingelheim, Germany) stocks of 10 mM were prepared in dimethyl sulfoxide (DMSO) and stored at -80°C.

Techniques: Transfection, Activity Assay, Control